^
    Back
    Association details:
    Biomarker:MCL1 amplification
    Cancer:Triple Negative Breast Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Genet
    Title:

    Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer

    Published date:
    03/16/2023
    Excerpt:
    ...univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05)....Our data indicate that ICI efficacy in patients with advanced TNBC may be predicted by 12 mutant ctDNA genes.
    DOI:
    10.3389/fgene.2023.1125970